DK1513551T3 - Vaccination med immun-isolerede celler, der producerer en immunomodulator - Google Patents

Vaccination med immun-isolerede celler, der producerer en immunomodulator

Info

Publication number
DK1513551T3
DK1513551T3 DK03759977.6T DK03759977T DK1513551T3 DK 1513551 T3 DK1513551 T3 DK 1513551T3 DK 03759977 T DK03759977 T DK 03759977T DK 1513551 T3 DK1513551 T3 DK 1513551T3
Authority
DK
Denmark
Prior art keywords
immunomodulator
vaccination
cells producing
relates
immune
Prior art date
Application number
DK03759977.6T
Other languages
English (en)
Inventor
Nicolas Mach
Original Assignee
Maxivax Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Maxivax Sa filed Critical Maxivax Sa
Application granted granted Critical
Publication of DK1513551T3 publication Critical patent/DK1513551T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/193—Colony stimulating factors [CSF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N11/00—Carrier-bound or immobilised enzymes; Carrier-bound or immobilised microbial cells; Preparation thereof
    • C12N11/02—Enzymes or microbial cells immobilised on or in an organic carrier
    • C12N11/04—Enzymes or microbial cells immobilised on or in an organic carrier entrapped within the carrier, e.g. gel or hollow fibres
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5152—Tumor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Plant Pathology (AREA)
  • Molecular Biology (AREA)
  • Dispersion Chemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK03759977.6T 2002-06-17 2003-06-17 Vaccination med immun-isolerede celler, der producerer en immunomodulator DK1513551T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP02013249A EP1374893A1 (en) 2002-06-17 2002-06-17 Vaccination with immuno-isolated cells producing an immunomodulator
PCT/EP2003/007140 WO2003105895A1 (en) 2002-06-17 2003-06-17 Vaccination with immuno-isolated cells producing an immunomodulator

Publications (1)

Publication Number Publication Date
DK1513551T3 true DK1513551T3 (da) 2010-03-08

Family

ID=29716769

Family Applications (2)

Application Number Title Priority Date Filing Date
DK03759977.6T DK1513551T3 (da) 2002-06-17 2003-06-17 Vaccination med immun-isolerede celler, der producerer en immunomodulator
DK09175526.4T DK2147682T3 (da) 2002-06-17 2003-06-17 Vaccination med immunisolerede celler til fremstilling af en immunmodulator

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK09175526.4T DK2147682T3 (da) 2002-06-17 2003-06-17 Vaccination med immunisolerede celler til fremstilling af en immunmodulator

Country Status (8)

Country Link
US (3) US20060024318A1 (da)
EP (3) EP1374893A1 (da)
AT (1) ATE447968T1 (da)
AU (1) AU2003246369A1 (da)
DE (1) DE60330004D1 (da)
DK (2) DK1513551T3 (da)
ES (2) ES2560105T3 (da)
WO (1) WO2003105895A1 (da)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8682619B2 (en) * 2005-12-14 2014-03-25 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8278094B2 (en) 2005-12-14 2012-10-02 The Invention Science Fund I, Llc Bone semi-permeable device
US8734823B2 (en) * 2005-12-14 2014-05-27 The Invention Science Fund I, Llc Device including altered microorganisms, and methods and systems of use
US8180920B2 (en) * 2006-10-13 2012-05-15 Rgb Networks, Inc. System and method for processing content
WO2009125332A1 (en) * 2008-04-07 2009-10-15 Peter Bromley New and safe procedure for immunization against infectious diseases agents
US8551749B2 (en) * 2009-04-23 2013-10-08 The Invention Science Fund I, Llc Device including bone cage and method for treatment of disease in a subject
CA2998991A1 (en) 2015-09-25 2017-04-20 Maxivax Sa Vaccination with immuno-isolated cells producing an immunomodulator
WO2018044888A1 (en) * 2016-08-29 2018-03-08 Chen James C Tumor vaccination systems, devices, and methods
US20230272334A1 (en) * 2020-07-27 2023-08-31 Arizona Board Of Regents On Behalf Of Arizona State University Artificial placenta vaccine for organ transplantation

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4680174A (en) * 1984-05-24 1987-07-14 Damon Biotech, Inc. Induction of immune response by immunization with encapsulated antigen-producing cells
US5904920A (en) * 1991-10-04 1999-05-18 Whitehead Institute For Biomedical Research Regulation of systemic immune responses utilizing cytokines and antigens
US5637483A (en) * 1991-10-04 1997-06-10 Whitehead Institute For Biomedical Research Irradiated tumor cell vaccine engineered to express GM-CSF
US5955095A (en) * 1992-04-22 1999-09-21 Brown University Research Foundation Microporous macrocapsules
US5679356A (en) * 1992-07-08 1997-10-21 Schering Corporation Use of GM-CSF as a vaccine adjuvant
CA2178902A1 (en) * 1993-12-14 1995-06-22 Drew Pardoll Controlled release of pharmaceutically active substances for immunotherapy
WO1998016246A1 (en) 1996-10-16 1998-04-23 Johns Hopkins University Cytokine enhanced immunotherapy for brain tumors
WO1998033520A1 (en) 1997-02-05 1998-08-06 Bystryn Jean Claude pH-SENSITIVE LIPOSOMES AND OTHER TYPES OF ENCAPSULATED VACCINES CONTAINING IMMUNOMODULATORS, AND METHODS FOR MAKING AND USING SAME
KR20010074426A (ko) * 1998-02-02 2001-08-04 추후제출 만능 면역조절 사이토킨-발현 방관자 세포주 및 관련조성물 및 제조방법 및 사용방법
US7250291B1 (en) * 1998-08-07 2007-07-31 Dana-Farber Cancer Institute Tumor antigens and uses thereof
CN100425287C (zh) * 1999-02-09 2008-10-15 理化学研究所 肿瘤疫苗
US6916640B2 (en) * 2000-10-12 2005-07-12 Agency For Science, Technology And Research Multi-layer cell encapsulation for tissue engineering
FR2822707A1 (fr) * 2001-04-03 2002-10-04 Neurotech Association d'un antigene tumoral et d'un systeme de delivrance d'une cytokine ou d'une chemokine a des fins d'immunotherapie du cancer
CA2485259A1 (en) * 2002-05-07 2003-11-20 Mcmaster University Microcapsules containing biomedical materials

Also Published As

Publication number Publication date
EP2147682A2 (en) 2010-01-27
US20080107686A1 (en) 2008-05-08
US20060024318A1 (en) 2006-02-02
WO2003105895A1 (en) 2003-12-24
AU2003246369A1 (en) 2003-12-31
ATE447968T1 (de) 2009-11-15
ES2560105T3 (es) 2016-02-17
EP1513551A1 (en) 2005-03-16
EP2147682A3 (en) 2012-07-25
EP2147682B1 (en) 2015-11-11
EP1374893A1 (en) 2004-01-02
ES2335490T3 (es) 2010-03-29
US20140341982A1 (en) 2014-11-20
DE60330004D1 (de) 2009-12-24
EP1513551B1 (en) 2009-11-11
DK2147682T3 (da) 2016-02-01
US9814682B2 (en) 2017-11-14

Similar Documents

Publication Publication Date Title
HK1083635A1 (en) Animal protein free media for cultivation of cells
WO2004058157A3 (en) Yeast-based vaccines as immunotherapy
DK1459766T3 (da) Adjuvanssammensætninger til forstærkning af immunresponser på polynukleotidbaserede vacciner
DE602004028468D1 (de) Haltung von immunantworten gegen mhc-klasse-i-beschränkte epitope, für prophylaktische oder therapeutische zwecke
IL132468A0 (en) A kit for inducing immune response against a tumor or a disease caused by an infection agent
WO2001095919A3 (en) A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
DK1187629T3 (da) Adjuvanssammensætning omfattende saponin og et immunostimulerende oligonucleotid
ATE461709T1 (de) Choline-bindende proteine derivate aus pneumokoken als impfstoff
CY1113044T1 (el) Παραλλαγματα αντιγονου αρχεγονων κυτταρων προστατη (psca) και υποαλληλουχιες εξ αυτων
FI970799A0 (fi) Mutanttientoroksiini, joka on tehokas ei-toksinen oraalinen adjuvantti
ATE149841T1 (de) Impfstoffe gegen krebs und infektionskrankheiten
ATE489968T1 (de) Proteosom-liposaccharid-vakzine-adjuvans
EP2385060A3 (en) Methods and compositions to elicit multivalent immune responses against dominant and subdominant epitopes, expressed on cancer cells and tumor stroma
JP2008512491A5 (da)
DK1513551T3 (da) Vaccination med immun-isolerede celler, der producerer en immunomodulator
ATE441420T1 (de) Interleukin-2 und gamma delta t zellaktivator enthaltende zusammensetzungen und deren verwendungen
DE60331725D1 (de) Therapeutische mittel als antikrebs impfstoffadjuvantien und deren therapeutische verfahren
DK1471936T3 (da) HIV-Vaccine og fremgangsmåde til anvendelse
BRPI0412913A (pt) meio para tratamento de infecções por leishmaniose
CY1109349T1 (el) Hsp60 απο arthrobacter
WO2003066833A3 (en) Use of recombinant hepatitis b core particles to develop vaccines against infectious pathogens and malignancies
WO2004002412A3 (en) A method and composition to elicit an effective autologous antitumoral immune response in a patient
DE60227367D1 (de) Modifizierter granulozyten stimulierender factor (g-csf) mit verringerter immunogenität
PL358081A1 (en) Inclusion bodies as antigenes in oral immunization of animals
WO2003054176A3 (en) Preparation of vaccines using photosensitizer and light